Achievement of Minimal Symptom Expression in Acetylcholine-Receptor Antibody-Positive Participants with Generalized Myasthenia Gravis and Effect on Disease-Specific Measures in ADAPT/ADAPT+ Studies
/0 Commenti/in GRUPPO 2, Uncategorized/da expomeetingSubcutaneous Efgartigimod PH20 Treatment in Participants With Generalized Myasthenia Gravis in ADAPT-SC+: Interim Analyses on Quality of Life, Efficacy, Tolerability, and Long-Term Safety
/0 Commenti/in GRUPPO 2, Uncategorized/da expomeetingAnkle Range of Motion asymmetry and motor functional tests: A Retrospective Analysis of 24 Months in Ambulant Boys with Duchenne Muscular Dystrophy (DMD)
/0 Commenti/in GRUPPO 2, Uncategorized/da expomeetingTreatment of active idiopathic inflammatory myopathies by inhibiting FcRn: Pre-registration report of ALKIVIA, a phase 2/3 trial with efgartigimod
/0 Commenti/in GRUPPO 2, Uncategorized/da expomeetingSEGRETERIA NAZIONALE AIM
Seguici sulle nostre pagine social
SEGRETERIA ORGANIZZATIVA FIRST CLASS
First Class S.r.l. Meetings and Conferences